Welcome to our dedicated page for Pharvaris N.V. SEC filings (Ticker: PHVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pharvaris N.V. filings document foreign private issuer disclosures for a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists. Form 6-K reports furnish financial results, business updates, investor presentations, clinical-study updates, annual general meeting voting results and materials incorporated by reference into Form F-3 and Form S-8 registration statements.
The filing record also covers capital-structure activity involving ordinary shares and pre-funded warrants, registration rights agreements, underwriting documents, share-based compensation and governance matters. These disclosures frame Pharvaris' development-stage operating expenses, financing activity, shareholder approvals and formal reporting obligations as a Nasdaq-listed foreign private issuer.
Pharvaris N.V. Chief Medical Officer Lu Peng reported a routine tax-related share withholding. On April 16, 2026, 226 common shares were disposed of at a fair market value of $28.78 per share to satisfy tax withholding obligations from restricted stock units that vested on April 11 and April 12, 2026. After this non‑market transaction, Lu Peng directly held 66,083 common shares.
Pharvaris N.V. Chief Executive Officer Berndt Modig reported a small open-market sale of company stock. On April 16, 2026, he sold 2,292 shares of Pharvaris common stock at a weighted average price of $28.6032 per share in a series of trades executed under a Rule 10b5-1 trading plan. These sales involved shares that include stock previously acquired upon vesting of restricted stock units. After the sale, he directly owns 139,792 shares of common stock and also has an indirect holding of 950,000 shares through Schoodic Management BV, an entity he controls, indicating he retains a substantial overall stake in the company.
PHVS affiliate files Rule 144 notice to sell 2,292 shares of Common Stock appearing as Restricted Stock Units with an intended sale date of 04/11/2026. The filing also reports prior 10b5-1 sales of 23,333 shares on 04/08/2026 for $647,283.26.
Pharvaris N.V. Principal Accounting Officer Anna Nijdam reported a routine tax-related share disposition. On the vesting of restricted stock units, the issuer withheld 548 shares of common stock at $26.63 per share to cover tax withholding obligations. After this withholding, Nijdam directly holds 48,940 common shares.
Pharvaris N.V. Chief Executive Officer Berndt Modig reported open-market sales of a total of 23,333 shares of common stock on April 9, 2026. The transactions were executed under a Rule 10b5-1 trading plan at weighted average prices of $27.7352 and $28.415 per share, across price ranges of $27.31–$28.30 and $28.32–$28.51. The shares sold include stock previously acquired upon vesting of restricted stock units. Following these sales, Modig holds 142,084 shares directly and 950,000 shares indirectly through Schoodif Management BV.